Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report
<h3>Abstract</h3><p dir="ltr">Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective first-line therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , |
| منشور في: |
2023
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513547355029504 |
|---|---|
| author | Meshaal Alanzi (21406994) |
| author2 | Mohammad Abu-Tineh (14829313) Lajos Szabados (16561323) MZ Sharaf Eldean (21406997) Sali Alatasi (14777713) Ruba Y Taha (14779351) Sarah A Elkourashy (21407000) |
| author2_role | author author author author author author |
| author_facet | Meshaal Alanzi (21406994) Mohammad Abu-Tineh (14829313) Lajos Szabados (16561323) MZ Sharaf Eldean (21406997) Sali Alatasi (14777713) Ruba Y Taha (14779351) Sarah A Elkourashy (21407000) |
| author_role | author |
| dc.creator.none.fl_str_mv | Meshaal Alanzi (21406994) Mohammad Abu-Tineh (14829313) Lajos Szabados (16561323) MZ Sharaf Eldean (21406997) Sali Alatasi (14777713) Ruba Y Taha (14779351) Sarah A Elkourashy (21407000) |
| dc.date.none.fl_str_mv | 2023-02-21T06:00:00Z |
| dc.identifier.none.fl_str_mv | 10.2147/ott.s394193 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Polatuzumab_Vedotin_in_a_Patient_with_Refractory_Burkitt_Lymphoma_a_Case_Report/29126747 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Oncology and carcinogenesis Burkitt’s lymphoma polatuzumab Lymphoma anti CD79b resistant lymphoma |
| dc.title.none.fl_str_mv | Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Abstract</h3><p dir="ltr">Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective first-line therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the treatment regimens. We report a 48-year-old male with stage II Burkitt’s lymphoma with no response to the first line of high-intensity chemotherapy. However, treatment with polatuzumab vedotin led to complete clinical remission for more than one year.</p><h2>Other Information</h2><p dir="ltr">Published in: OncoTargets and Therapy<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.2147/ott.s394193" target="_blank">https://dx.doi.org/10.2147/ott.s394193</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_e6500fa4703780d3ecd8838a0c2bd340 |
| identifier_str_mv | 10.2147/ott.s394193 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/29126747 |
| publishDate | 2023 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case ReportMeshaal Alanzi (21406994)Mohammad Abu-Tineh (14829313)Lajos Szabados (16561323)MZ Sharaf Eldean (21406997)Sali Alatasi (14777713)Ruba Y Taha (14779351)Sarah A Elkourashy (21407000)Biomedical and clinical sciencesCardiovascular medicine and haematologyOncology and carcinogenesisBurkitt’s lymphomapolatuzumabLymphomaanti CD79bresistant lymphoma<h3>Abstract</h3><p dir="ltr">Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective first-line therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the treatment regimens. We report a 48-year-old male with stage II Burkitt’s lymphoma with no response to the first line of high-intensity chemotherapy. However, treatment with polatuzumab vedotin led to complete clinical remission for more than one year.</p><h2>Other Information</h2><p dir="ltr">Published in: OncoTargets and Therapy<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.2147/ott.s394193" target="_blank">https://dx.doi.org/10.2147/ott.s394193</a></p>2023-02-21T06:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.2147/ott.s394193https://figshare.com/articles/journal_contribution/Polatuzumab_Vedotin_in_a_Patient_with_Refractory_Burkitt_Lymphoma_a_Case_Report/29126747CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/291267472023-02-21T06:00:00Z |
| spellingShingle | Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report Meshaal Alanzi (21406994) Biomedical and clinical sciences Cardiovascular medicine and haematology Oncology and carcinogenesis Burkitt’s lymphoma polatuzumab Lymphoma anti CD79b resistant lymphoma |
| status_str | publishedVersion |
| title | Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report |
| title_full | Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report |
| title_fullStr | Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report |
| title_full_unstemmed | Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report |
| title_short | Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report |
| title_sort | Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Oncology and carcinogenesis Burkitt’s lymphoma polatuzumab Lymphoma anti CD79b resistant lymphoma |